Lily Wong

Partner
​PwC Taiwan

Lily Wong is a Deals Partner at PwC Taiwan who specialises in M&A advisory services, including strategic advice, due diligence and valuation analysis. Lily has a wealth of experience of conducting buy-side advisory engagements for strategic and financial buyers, as well as carve-out and sell-side support, in addition to market assessments and commercial due diligence for international companies and investors looking to enter Taiwan.
Lily works with clients across a range of industries, including the financial services, healthcare, pharmaceutical and life sciences, retail and consumer sectors, etc. Her advisory experience in the health industries includes:

Deals advisory services for local pharma and medical device companies seeking strategic/financial investors;

Sell-side lead advisor to a listed pharmaceutical company seeking to divest its China-based assets;

Valuation and financial due diligence services for several domestic biopharmaceutical companies;

Development of a comprehensive market-entry strategy for a leading Japanese pharmaceutical company; and

Various market assessment projects for leading multinational pharmaceutical companies operating in Taiwan.
Lily holds CPA licenses from both Taiwan and the US, and is also a Fellow of Life Management Institute. She has a bachelor’s degree in business administration from the National Taiwan University, and a Master’s of Accounting degree from the University of Illinois at Urbana-Champaign in the US.

Speech title & Synopsis

Empowering Taiwanese biomedical startups through international collaboration

The rapid evolution of new technologies, such as AI and Big Data, have empowered startups around the world to deliver innovative solutions across industries. They play a particularly key role in the digital health transformation which is reshaping how services are delivered and improving patient outcomes. This presentation will look at how Taiwan’s biomedical startups can benefit from international collaborations to accelerate innovation performance.
The first part will provide an overview of the current state of Taiwan’s startup ecosystem, which draws from the latest market survey by PwC Taiwan and the Taiwan Institute of Economic Research. This found that local AI startups are making considerable progress, and corporate startup engagement (CSE)  is starting to take root in Taiwan. Together, these trends indicate the potential for greater business collaboration with innovative startups.
Such collaboration is becoming increasingly important in Taiwan’s biomedical industry, where the current focus is on the development of precision health and new medical technologies. International companies are showing growing interest in collaboration and investment opportunities in these areas to take advantage of the agility of local startups and other firms when it comes to identifying market niches with the potential for more innovation.
Taiwanese businesses are similarly keen to collaborate with larger multinationals to speed up the development of their health and biomedical innovations and expand their market reach internationally. The second part of the presentation will share several illustrative cases of biomedical-related collaborations between startups and international companies on how they help drive innovative solutions and foster new health industry ecosystems.